- Third Quarter 2008 Earnings Conference Call on October 30 -
- Presentation at Oppenheimer's 19th Annual Healthcare Conference on
November 4 - - Annual Analyst Day for Institutional Investors and Financial Analysts on
November 7 -
SAN DIEGO, Oct. 13 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will webcast three upcoming investor events.
First, Gen-Probe will release its third quarter 2008 financial results on Thursday, October 30, 2008 at approximately 4:00 pm Eastern Time (ET), followed by a conference call with management at 4:30 pm ET. The conference call will be webcast live and may be accessed on the investors section of the Company's web site at http://www.gen-probe.com. An archived version of the webcast will be available on the same web site for at least 90 days. A telephone replay also will be available for 24 hours after the call ends. To access the replay, please call 866-505-9257 (US) or 203-369-1881 (international).
Second, the Company will present at Oppenheimer's 19th Annual Healthcare Conference in New York on Tuesday, November 4, 2008 at 12:40 pm ET. The presentation is scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website. The webcast will be available for 30 days following the event.
Third, Gen-Probe will webcast its annual meeting with institutional investors and sell-side analysts in San Diego on Friday, November 7, 2008, at 8 am Pacific Time (11 am ET). The meeting, which will feature presentations on Gen-Probe's current business and future growth strategies, will conclude at approximately 11 am Pacific Time (2 pm ET). Institutional investors and sell-side analysts can RSVP to attend in person by contacting Paula Izidoro at email@example.com. Please note the new date and time. Others may access a live webcast through a link on the investors section of Gen-Probe's website. The webcast will be available for 30 days following the event.
Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to http://www.gen-probe.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations, beliefs,
plans, objectives, assumptions or future events or performance are not
historical facts and are forward-looking statements. Forward-looking
statements are not guarantees of performance. They involve known and
unknown risks, uncertainties and assumptions that may cause actual results,
levels of activity, performance or achievements to differ materially from
those expressed or implied by any forward-looking statement. For
information about risks and uncertainties we face and a discussion of our
financial statements and footnotes, see documents we have filed with the
SEC, including the Form 10-Q for the period ended June 30, 2008, and all
subsequent periodic filings made with the SEC. We assume no obligation and
expressly disclaim any duty to update any forward-looking statement to
reflect events or circumstances after the date of this press release or to
reflect the occurrence of unanticipated events.
|SOURCE Gen-Probe Incorporated|
Copyright©2008 PR Newswire.
All rights reserved